Ultimovacs’ UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement